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cells that have been conveyed to that organ by the arteries [3]. 
Several theories have been postulated to account for the low 
incidence of metastases to the spleen compared to other 
parenchymatous organs [4], including a possible role of spleen 
contractions in forcing the blood from the sinusoids into the 
splenic vein which keeps tumour cells in constant motion. 
The 2 patients we describe here had spleen metastases from 
ovarian and colonic cancer in the absence of other distant organ 
involvement. These unusual presentations of advanced disease 
raise the question of whether an underlying condition may 
represent a risk factor for spleen colonisation in subjects with 
solid tumours. Both patients had liver cirrhosis causing portal 
hypertension. When the portal venous pressure rises, blood 
stasis, retrograde blood flow and diversion of portal blood into 
systemic veins, in an attempt o decompress the portal system, 
can occur. We suggest, that in such conditions, a neoplastic 
embolus may reach the spleen via the mesenteric veins and by 
retrograde blood flow in the splenic vein. Moreover, implan- 
tation of neoplastic ells may be facilitated by blood stasis which 
increases the time of contact with the splenic tissue. The 2 cases 
described here seem to support this hypothesis. Patient 1 had 
primary ovarian cancer involving the sigmoid colon and patient 2 
had a primary tumour of the descending colon; the venous 
system of the left region of the colon drains into the portal 
circulation via the inferior mesenteric vein which enters the 
splenic vein. 
Whether neoplastic cells from tumours draining into the 
portal system can more easily seed the spleen in patients with 
portal hypertension needs to be confirmed. However, based on 
our experience, we suggest a more careful evaluation of the 
spleen at intervention and during follow-up in these subjects. 
1. Berge T. Splenic metastases: frequencies and patterns. Acta Path01 
Microbial Stand 1974,82,49%506. 
2. Morgenstem L, Rosenberg J, Geller SA. Tumors of the spleen. 
WorldJSurg 1985,9,46U76. 
3. Marymount JH Jr, Gross S. Patterns of metastatic cancer in the 
spleen. AmJ Clin Path01 1963,40,58-60. 
4. Klein B, Stem M, Kuten A, et al. Splenomegaly and solitary spleen 
metastasis in solid tumors. Cancer 1987,60, 100-102. 
European&zmulofCmarVol. 31A,No. 11, pp. 18861887,1995. 
Copyright 0 1995 Ekvier Science Ltd 
Printed in Great Britain. All rights reserved 
095%8049/95 $9.50 + 0.00 
Problems with the Evaluation of 
Response After Induction 
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C. H. van Eijck and T.A.W. Splinter 
INDUCTION CHEMOTHERAPY has become part of the standard 
treatment of locally advanced breast cancer. Recently, it has 
also been used to induce “lumpectability” in tumours larger than 
3 cm [l-3] or as part of induction chemoradiotherapy [4]. 
Moreover, the response to induction chemo(radio)therapy may 
be used as a prognostic factor [ 5, 61. 
Since 1990, we have performed a prospective study of pre- 
operative induction chemotherapy in patients with different 
stages of breast cancer. After clinical examination, mammogra- 
phy, ultrasound and cytological proof of the primary tumour, 
the patients were treated with cyclophosphamide 100 mg/m2 
orally days 1-14, doxorubicin 30 mg/m2 and 5-Fluorouracil 
600 mg/m2 intravenously (i.v.) on days 1 and 8. Courses were 
repeated every 4 weeks. After two and four courses, the response 
of the primary tumour was assessed by palpation, mammography 
and ultrasound. For stable disease or progression after the 
hrst two courses, the patient underwent surgery. Responders 
received another two courses of chemotherapy and then surgery. 
Standard criteria of response according to the WHO [7] were 
used. The study is ongoing. However, in a recent analysis, three 
problems with the evaluation of response were observed in 7 of 
the 22 patients (Table 1). In patients l-3, who had major clinical 
responses, avery small lesion of viable invasive ductal carcinoma 
(IDC) was seen adjacent to extensive ductal carcinoma in situ 
(DCIS) in the resection material. These findings indicate a 
discrepancy between clinical and pathological complete 
remissions, but more importantly a lack of chemosensitivity ‘of 
DCIS. Since the extent of DCIS is not predicted by pre- 
chemotherapy cytology nor expected from the distribution of 
mammographic microcalcilications [S, 91, extensive DCIS may 
still be found in resection material after a major response to 
induction chemotherapy of the invasive tumour. 
Table 1, Patients’ characteristics 
Patient Clinical stage Response Surgery Histopathology 
1 T2N2 (2.5 cm) CR L* DCIS IDC 
2 TlN2 (2 cm) CR Q* DCIS IDC 
3 T4bN2 (6 cm) PR (1.8 cm) M DCIS IDC 
4 T2N1(4 cm) CR L* - IDC 
5 TlN2 (1.5 cm) MR(l.l cm) L* - ILC 
6 T2NO (4 cm) MR (2.1 cm) L* LCIS ILC 
7 T4cN1(5 cm) PR (1.4 cm) M - ILC 
CR, complete response; PR, partial response; MR, minor response; 
L, lumpectomy; Q, quadrantectomy; M, radical mastectomy; DCIS, 
ductal carcinoma in situ; LCIS, lobular carcinoma in sim; IDC, invasive 
ductal carcinoma; ILC, invasive lobular carcinoma. *After ultrasound 
localisation. 
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A second problem, related to the discrepancy between clinical 
and pathological complete remission, is the localisation of the 
prechemotherapy site of the tmmour in a case of clinical complete 
remission (CR). Patient 4 had obtained a clinical CR and 
underwent lumpectomy after ultrasound localisation of a doubt- 
ful remaining lesion. In the margin of the lump, a very small 
amount of viable IDC was found, and more IDC in the mastec- 
tomy specimen. 
The third problem was a major discrepancy between the 
clinical and pathological response. 3 patients (5-7) had a small 
lesion after induction chemotlherapy. In 2 patients, a lumpec- 
tomy and in 1 patient a mastectomy was performed, which were 
irradical because of the presen.ce of multifocal tumour rests. In 
all patients, invasive lobular carcinoma (ILC) was found, which 
is known for its multicentric diffuse growth pattern [ 10, 111. 
Although there bve been reports on the discrepancy between 
clinical and pathological evaluations of response after induction 
chemotherapy in breast cancer [ 1, 121, our experience indicates 
a cautious approach should be taken in the use of chemotherapy 
to induce “lumpectability”, and it is recommended that the 
response is verified pathologically, especially in patients with 
CIS and/or ILC. 
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Sequential Chemotherapy, Beta 
Interferon, Retinoids and Tamoxifen 
in the Treatment of Metastatic Breast 
Cancer. A Pilot Study 
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A. Fingerhut and L. Frati 
CHEMOTHERAPY (CT) for metastatic breast cancer remains palli- 
ative, and no clear therapeutic strategy has yet been established 
for responders with subclinical minimal residual disease. In vitro 
studies have shown that interferons (IFN) and retinoids inhibit 
the growth of oestrogen receptor positive (ER+) and negative 
(ER-) breast cancer cell lines [ 1, 21, and sensitise them to the 
antiproliferative action of anti-oestrogens through the enhance- 
ment of oestrogen receptors [3-6]. 
This rationale led us to undertake a phase II pilot study to 
explore the attractive working hypothesis of administering two 
non-cross-resistant CT regimens, followed by maintenance ther- 
apy, with P-IFN, retinoids and tamoxifen (TAM) in a group of 
patients with poor prognosis metastatic breast cancer. Eligibility 
criteria included pathologically documented measurable or eval- 
uable breast cancer; age ~75 years; performance status ~3; no 
anthracycline chemotherapy; recovery from previous radio- 
therapy and/or CT with WBC count >3500 mm3, platelet count 
> 100 000 mm3; normal kidney and cardiovascular function and 
written informed consent. Induction CT was 4-epidoxorubicin 
60 mg/m’/day 1, cyclophosphamide 500 mg/m2/day 1, vincris- 
tine 2 mg day 1,5-fluorouracil500 mg/m2 days 1 and 8, predni- 
sone 50 mg days l-5, and this was repeated every 3 weeks for 
six courses, followed by mitomycin-c and mitoxantrone 10 mg/ 
m2, methotrexate 40 mg/m2 day 1 for two courses every 4 weeks. 
Maintenance therapy for responders was p-IFN 1 x lo6 IU/m2 
three times a week, retinyl pahnitate 50000 IU twice daily, 
TAM 10 mg three times daily, until disease relapse. 
Responses and toxicities were categorised according to WHO 
criteria. 36 patients were enrolled in the trial from January 1987 
to January 1992. Median age was 61 years (range 37-74); 4 were 
premenopausal and 32 postmenopausal. Median disease-free 
interval was 19 months (range l-28) for 27 patients, while 9 
patients had metastases atthe time of diagnosis. All patients had 
Correspondence to F. Recchia t Via Rossetti 1, 67056 LUCO DE1 
MARS1 (AQ), Italy. 
F. Recchia is at the Division of Internal Medicine (Oncology Unit), Civil 
Hospital, 67051 Avezzano; S. Rea, A. Fingerhit, F. Reccbia and L. 
Frati are also at “Centro di Riferimento Oncoloaico France-Italiano”, 
Moterotondo, Rome; S. Rea is also at the Surgi&i Oncology University 
of L’Aquila; G. Corrao is at the Medical Statistics and Biometry 
University of L’Aquila; and L. Frati is also at the General Pathology 
University “La Sapienza”, Rome, Italy. 
A. Fingerhut was a visiting Professor at the Surgical Oncology University 
of L’Aquila, Italy. 
Revised 12 Jun. 1995; accepted 7Jul. 1995. 
